A PYMNTS Company

U.S.: FTC places conditions on Watson’s acquisition of Actavis

By  |  October 16, 2012

The Federal Trade Commission (FTC) has required Watson Pharmaceuticals and Actavis Inc, both global pharmaceutical companies specializing in the development, production, and marketing of generic and branded drugs, to sell their rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full Content: FTC

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Related Content: Watson Pharmaceutical confirms favorable ruling in antitrust litigation

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.